A respiratory syncytial virus (RSV) F protein nanoparticle vaccine focuses antibody responses to a conserved neutralization domain-Reference-Cited by-同舟云学术

A respiratory syncytial virus (RSV) F protein nanoparticle vaccine focuses antibody responses to a conserved neutralization domain

Published:2020-05-19 Issue:47 Volume:5 Page:
ISSN:2470-9468
Container-title:Science Immunology
language:en
Short-container-title:Sci. Immunol.

Author:

Swanson Kurt A.¹^ORCID,Rainho-Tomko Jennifer N.²^ORCID,Williams Zachary P.²^ORCID,Lanza Lilibeth²,Peredelchuk Michael²,Kishko Michael³^ORCID,Pavot Vincent⁴^ORCID,Alamares-Sapuay Judith³,Adhikarla Haritha³,Gupta Sankalp³,Chivukula Sudha³,Gallichan Scott⁵,Zhang Linong³,Jackson Nicholas³^ORCID,Yoon Heesik²^ORCID,Edwards Darin²^ORCID,Wei Chih-Jen¹^ORCID,Nabel Gary J.⁶^ORCID

Affiliation:

1. Sanofi, 270 Albany, Cambridge, MA 02139, USA.

2. Sanofi Pasteur VaxDesign, 2501 Discovery Drive, Suite 300, Orlando, FL 32826, USA.

3. Sanofi Pasteur, 38 Sidney Street, Cambridge, MA 02139, USA.

4. Sanofi Pasteur, 1541 Avenue Marcel Mérieux, Marcy l’Etoile, France.

5. Sanofi Pasteur, 95 Willowdale Blvd, Toronto, Ontario, Canada.

6. Sanofi, 640 Memorial Drive, Cambridge, MA 02139, USA.

Abstract

A glycan-modified RSV nanoparticle vaccine displaying multimeric pre-F protein focuses antibody responses on neutralizing epitopes.

Funder

Sanofi Genzyme

Publisher